Table 1.

Correlation of nm23-H1 with TIA-1 expression and prognostic characteristics in patients with PTCL-NOS

CharacteristicNumber of patientsnm23-H1(+), an (%)PTIA-1(+),bn (%)P
Age, y
 ≤604621 (45.7)0.7811 (23.9)0.59
 >605624 (42.9)11 (19.6)
WHO PS
 0, 16426 (40.6)0.3613 (20.3)0.67
 2–43819 (50)9 (23.6)
Serum LDH level
 Normal2210 (45.5)0.895 (22.7)0.89
 >Normal8035 (43.8)17 (21.2)
Ann Arbor stage
 I, II2412 (50)0.516 (25)0.64
 III, IV7833 (42.3)16 (20.5)
BM involvement
 Absent8133 (40.7)0.1819 (23.4)0.38
 Present2112 (57.1)3 (14.3)
PIT
 Groups 1/24315 (34.9)0.00511 (23.9)0.39
 Groups 3/45930 (50.8)11 (19.6)
Therapeutic effect
 CR6623 (34.8)0.00418 (27.3)0.06
 Non-CR3622 (61.1)4 (11.1)